Financial News

Krsnaa Diagnostics files IPO papers with Sebi; firm receives heavy demand for PCR testing amid COVID-19

Products You May Like

Krsnaa Diagnostics, COVID-19, IPOThe general public concern includes recent concern of fairness shares price Rs 400 crore and an offer-for-sale (OFS) of 94 lakh fairness shares

Krsnaa Diagnostics filed draft papers with the market regulator Securities and Alternate Board of India (Sebi) for an preliminary public providing (IPO). The general public concern includes a recent concern of fairness shares price Rs 400 crore and an offer-for-sale (OFS) of 94 lakh fairness shares of a face worth of Rs 5 per share by present shareholders and promoters. The important thing stakeholders taking part within the OFS are Phi Capital Trust’s Phi Capital Progress Fund-I (16 lakh fairness shares), Kitara PIIN 1104 (33.40 lakh shares), Somerset Indus Healthcare Fund (44.54 lakh fairness ) and Lotus Administration Options (21,380 shares). The ebook operating lead managers to the IPO are JM Financial, DAM Capital Advisors, Equirus Capital Personal Ltd, and IIFL Securities, whereas the registrar to the problem is KFin Applied sciences Personal Ltd. Fairness shares are anticipated to be listed on BSE and NSE.

Key particulars of Krsnaa Diagnostics IPO

– Krsnaa Diagnostics trade listed friends are Metropolis Healthcare and Dr. Lal Pathlabs Ltd. The common trade P/E ratio is 97.18x.

Associated Information

– Krsnaa Diagnostics has deliberate to make use of the web proceeds in the direction of financing the price of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra price Rs 150.8 crore. Whereas Rs 125.7 crore will probably be used for reimbursement and/or pre-payment in full or in a part of sure borrowings availed by the corporate and in the direction of normal company functions.

– For the 9 months ended December 31, 2020, Krsnaa Diagnostics reported a revenue of Rs 195 crore, whereas income from operations stood at Rs 300 crore.

– Krsnaa Diagnostics in session with its book-running managers could take into account a pre-IPO placement of Rs 200 crore from anchor buyers, based on DRHP.

– The corporate has skilled heavy demand for PCR testing because of the COVID-19 pandemic, which has had a constructive affect on its general testing quantity, the length and stage of the demand for, and reimbursement for, COVID-19 molecular testing was unsure.

– Krsnaa Diagnostics may additionally expertise an antagonistic affect on money collections and provide chain disruptions, together with shortages, delays and worth will increase in testing tools and provides, because of the affect of the COVID-19 pandemic.

– The diagnostic agency operated over 1,800 diagnostic centres throughout 13 states as of December 31, 2020. It additionally operates a teleradiology reporting hub in Pune. Every of its diagnostic centres and notably the teleradiology reporting hub is important to its operations.

– Krsnaa Diagnostics rivals embody diagnostic healthcare service suppliers in India, hospital-based diagnostic centres, impartial scientific laboratories, different smaller-scale suppliers of diagnostic companies (with extra established native and regional presence in sure geographies) similar to pathology, radiology laboratories and preventive care suppliers in addition to worldwide service suppliers which can set up and broaden their operations in future.

– The corporate is dependent upon third-party distributors and suppliers to obtain its imaging tools, testing tools and reagents and it enters into contractual preparations with them.

Get stay Stock Prices from BSE, NSE, US Market and newest NAV, portfolio of Mutual Funds, Try newest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and observe us on Twitter.

Monetary Categorical is now on Telegram. Click here to join our channel and keep up to date with the most recent Biz information and updates.

Products You May Like